Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2039

Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.

Patents
1,782

Quick answer

1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10358421

    Piperidine derivatives as HDAC1/2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10357570

    Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron

    Heron Therapeutics, Inc. · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10357553

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    PrimeVax Immuno-Oncology · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10358495

    Anti-LAG3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10358487

    Anti-ANGPTL3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10358481

    Engineered antibody constant domain molecules

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10358501

    HER3 specific monoclonal antibodies for diagnostic and therapeutic use

    The Board of Regents of the University of Texas System · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10358447

    Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same

    ARBUTUS BIOPHARMA CORPORATION · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10357505

    Prodrugs of 2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 2019224329

    Incremental Dose Finding in Controlled-Release PTH Compounds

    ASCENDIS PHARMA BONE DISEASES AS [DK] · Granted Thu Jul 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jul 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10363246

    Methods and compositions for treatment of epileptic disorders

    OVID THERAPEUTICS INC. · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10363294

    Yeast-brachyury immunotherapeutic compositions

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10363289

    Mutant OPAA enzyme with increased catalytic efficiency on GP

    The United States of America as represented by the Secretary of the Army · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10363241

    Substituted imidazole derivatives and methods of use thereof

    VTV THERAPEUTICS LLC · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10363288

    Insulin mimotopes and methods of using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10363273

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10363282

    Analogs of C5a and methods of using same

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10363245

    Methods for treating CNS lesions

    The Board of Regents of the University of Texas System · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10363237

    Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase

    The Regents of the University of California · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10363213

    Immunogenic composition against Campylobacter jejuni

    United States of America as represented by the Secretary of the Air Force · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10363232

    Compositions and methods for treating severe pain

    Infirst Healthcare Limited · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10363312

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10363311

    Engineered primate cystine/cysteine degrading enzymes as antineogenic agents

    The Board of Regents of the University of Texas System · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10363319

    Glycoconjugates and methods for their use

    The Board of Regents of the University of Texas System · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10364227

    Therapeutic compounds

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10364238

    N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10363286

    Peptide inhibition of CCR3-mediated diseases or conditions

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10364252

    Oxabicycloheptane prodrugs

    Lixte Biotechnology, Inc. · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10364275

    Methods for treating inflammatory responses or diseases caused by inflammation using ApoA-I binding protein (APOA1BP)

    The Regents of the University of California · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10364431

    Compositions for treating muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10364258

    Heteroaryl inhibitors of PDE4

    Tetra Discovery Partners · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10363293

    Vaccine composition

    TURNSTONE LIMITED PARTNERSHIP · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10364433

    Modulation of AGPAT5 expression

    The Regents of the University of California · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10363244

    Compositions comprising metformin and a glucokinase activator

    VTV THERAPEUTICS LLC · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10363247

    (S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer

    Karyopharm Therapeutics Inc. · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10363274

    Renal cell populations and uses thereof

    inRegen · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10363261

    Enolase inhibitors and methods of treatment therewith

    The Board of Regents of the University of Texas System · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10364473

    Fast diagnosis and personalized treatments for acne

    The Regents of the University of California · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10364295

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10364233

    Piperidine derivative and methods of use thereof

    VTV THERAPEUTICS LLC · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10363301

    Stabilized influenza hemagglutinin stem region trimers and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10363292

    Vaccination with anti-tick antigens to control multiple tick species and disease transmission in white-tailed deer and other host animals

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10363248

    Salts of heterocyclic modulators of HIF activity for treatment of disease

    The Board of Regents of the University of Texas System · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. EP 3515433

    DIE BLUT-HIRN-SCHRANKE PASSIERENDE DOPAMIN-B-HYDROXYLASE-INHIBITOREN

    BIAL PORTELA & Cª S A [PT] · Granted Wed Jul 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Jul 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10370439

    Prevention of tissue ischemia and related methods

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10370659

    Compounds and methods for increasing antisense activity

    Ionis Pharmaceuticals, Inc. · Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10370666

    Ketohexokinase (KHK) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10370680

    Method of treating factor IX deficiency using nuclease-mediated targeted integration

    Sangamo Therapeutics, Inc. · Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2039?

1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.